Ovid Therapeutics (OVID) News Today $1.17 -0.01 (-0.85%) (As of 10/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 Time Period Ovid Therapeutics: Promising Safety Profile and Growth Potential Underpin Buy RatingOctober 16 at 10:30 AM | markets.businessinsider.comDravet Syndrome Drug Pipeline Research Report 2024: Therapeutic Assessment, Emerging Drugs, Pipeline Development Activities, Competitive LandscapeOctober 14 at 1:33 PM | uk.finance.yahoo.comKinderhook-Ovid sewer rates increase with maintenance contract awardOctober 12, 2024 | news.yahoo.comAnalysts Set Ovid Therapeutics Inc. (NASDAQ:OVID) Target Price at $4.70October 7, 2024 | americanbankingnews.comOvid Therapeutics Inc. (NASDAQ:OVID) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Ovid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating, four hOctober 4, 2024 | marketbeat.comBuy Rating Affirmed for Ovid Therapeutics on Promising Safety Profile and Robust Pipeline ProgressOctober 1, 2024 | markets.businessinsider.comWill Ovid Therapeutics (NASDAQ:OVID) Spend Its Cash Wisely?October 1, 2024 | finance.yahoo.comDriehaus Capital Management LLC Invests $1.08 Million in Ovid Therapeutics Inc. (NASDAQ:OVID)Driehaus Capital Management LLC acquired a new stake in shares of Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 1,400,191 shares of the company's stock, valued atSeptember 30, 2024 | marketbeat.comOvid-Elsie offense shines again in 42-7 win over MontroseSeptember 29, 2024 | msn.comOppenheimer Sticks to Their Hold Rating for Ovid Therapeutics (OVID)September 27, 2024 | markets.businessinsider.comPromising Neurology Breakthrough: Ovid Therapeutics’ OV329 Shows Safety and Efficacy PotentialSeptember 27, 2024 | markets.businessinsider.comOvid Therapeutics Presents Pre-Clinical Study Results Demonstrating OV329 Does Not Accumulate in Animal Eyes in Contrast with VigabatrinSeptember 27, 2024 | markets.businessinsider.comMereo BioPharma Group plc (MAH0.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comExscientia plc (0RK.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comPsychedelic therapies are coming to Europe, but face barriers before reaching patientsSeptember 24, 2024 | msn.comOvid-Elsie continues to roll with 42-7 win over DurandSeptember 21, 2024 | msn.comOvid Therapeutics (NASDAQ:OVID) Stock Passes Below 50 Day Moving Average of $1.06Ovid Therapeutics (NASDAQ:OVID) Shares Pass Below 50-Day Moving Average of $1.06September 19, 2024 | marketbeat.comOvid Therapeutics appoints new president and COOSeptember 13, 2024 | uk.investing.comOvid Therapeutics names new President and COOSeptember 13, 2024 | uk.investing.comOvid Therapeutics Inc.: Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future GrowthSeptember 12, 2024 | finanznachrichten.deMeg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future GrowthSeptember 11, 2024 | globenewswire.comTriArm Therapeutics Appoints Douglas E. Williams, Ph.D., as Chief Executive OfficerSeptember 9, 2024 | markets.businessinsider.comOvid Therapeutics Inc. (NASDAQ:OVID) Receives Average Recommendation of "Moderate Buy" from AnalystsOvid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) has been given an average rating of "Moderate Buy" by the seven research firms that are covering the firm, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one haSeptember 9, 2024 | marketbeat.comBTIG downgrades Athira Pharma (ATHA) to a HoldSeptember 4, 2024 | markets.businessinsider.comOvid Therapeutics Inc. (OVID)August 31, 2024 | finance.yahoo.comEvidence Still Lacking for Iron Deficiency Screening, Supplementation in PregnancyAugust 21, 2024 | msn.comExpert Outlook: Ovid Therapeutics Through The Eyes Of 7 AnalystsAugust 19, 2024 | benzinga.comH.C. Wainwright Reaffirms Their Buy Rating on Ovid Therapeutics (OVID)August 19, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Ovid Therapeutics (NASDAQ:OVID)HC Wainwright reiterated a "buy" rating and set a $3.00 price objective on shares of Ovid Therapeutics in a research report on Monday.August 19, 2024 | marketbeat.comOvid Therapeutics Inc (1OT.SG)August 18, 2024 | nz.finance.yahoo.comOvid Therapeutics Inc. to Post Q3 2024 Earnings of ($0.15) Per Share, B. Riley Forecasts (NASDAQ:OVID)Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Equities research analysts at B. Riley boosted their Q3 2024 EPS estimates for shares of Ovid Therapeutics in a research report issued to clients and investors on Tuesday, August 13th. B. Riley analyst K. Patel now expects that the company willAugust 16, 2024 | marketbeat.comBuy Rating Justified by Ovid Therapeutics’ Clinical Progress and Strong FinancialsAugust 15, 2024 | markets.businessinsider.comOvid Therapeutics Inc. Forecasted to Earn FY2028 Earnings of ($0.78) Per Share (NASDAQ:OVID)Ovid Therapeutics Inc. (NASDAQ:OVID - Free Report) - Stock analysts at B. Riley issued their FY2028 EPS estimates for Ovid Therapeutics in a research note issued to investors on Tuesday, August 13th. B. Riley analyst K. Patel forecasts that the company will earn ($0.78) per share for the year. B.August 15, 2024 | marketbeat.comBuy Rating Affirmed for Ovid Therapeutics Amid Strong Clinical Progress and Promising Neurological PipelineAugust 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ovid Therapeutics Amid Promising Pipeline and Stable Financial OutlookAugust 15, 2024 | markets.businessinsider.comOvid Therapeutics Inc.: Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial ResultsAugust 14, 2024 | finanznachrichten.deOvid Therapeutics Reports Business Updates and Second Quarter 2024 Financial ResultsAugust 13, 2024 | globenewswire.comOvid Therapeutics Appoints Dr. Amanda Banks, Experienced Biotech Leader & Physician as Chief Development OfficerAugust 8, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDAugust 3, 2024 | globenewswire.comOVID Investors Have Opportunity to Join Ovid Therapeutics Inc. Fraud Investigation with the Schall Law FirmAugust 2, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDAugust 1, 2024 | prnewswire.comOvid Therapeutics to Present at Upcoming August Investor ConferencesJuly 30, 2024 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Ovid Therapeutics (OVID) and Dexcom (DXCM)July 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Ovid Therapeutics on Advisory Expansion and Promising Epilepsy Drug ProspectsJuly 26, 2024 | markets.businessinsider.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDJuly 26, 2024 | globenewswire.comOvid Therapeutics (NASDAQ:OVID) Receives Buy Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $3.00 price objective on shares of Ovid Therapeutics in a research note on Friday.July 26, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDJuly 24, 2024 | prnewswire.comOvid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and EpileptologistsJuly 23, 2024 | globenewswire.comOvid Therapeutics Inc. (NASDAQ:OVID) Given Average Recommendation of "Moderate Buy" by AnalystsShares of Ovid Therapeutics Inc. (NASDAQ:OVID - Get Free Report) have been given a consensus rating of "Moderate Buy" by the six research firms that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and four have issueJuly 21, 2024 | marketbeat.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ovid Therapeutics Inc. - OVIDJuly 20, 2024 | globenewswire.com Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address WARNING: “Buffett Indicator” flashing for first time in 50 years (Ad)The stock market collapsed and didn't recover for an entire decade. And what we're facing today could be even worse. That's why the actions you take in the next 90 days could be crucial for your financial future. Take these 4 steps today to protect your retirement NOW OVID Media Mentions By Week OVID Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OVID News Sentiment▼0.640.71▲Average Medical News Sentiment OVID News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OVID Articles This Week▼32▲OVID Articles Average Week Get Ovid Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: IMUX News TXMD News FHTX News ACIU News CGC News STRO News DSGN News KMDA News ACB News AVIR News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OVID) was last updated on 10/17/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredRetire off just one stock ticker?ONE AI Stock is All You Need... There are over 6,000 stocks listed in the market right now. They will NOT m...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMassive trading opportunity begins by October 21 October 21 could spark a mania among “next-generation” AI stocks. That’s the newest prediction from a Wall Str...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ovid Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ovid Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
